Yazar "Sayin, Sezin" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma(Sage Publications Ltd, 2022) Gokyer, Ali; Kucukarda, Ahmet; Kostek, Osman; Gokmen, Ivo; Ozcan, Erkan; Sayin, Sezin; Tastekin, EbruObjective: To evaluate clinical and demographic characteristics and the results of cytotoxic treatments of KRAS(G12C), KRAS(other), and next-generation sequencing (NGS) panel negative patients. Methods: NGS data of 1264 patients with non-small cell lung cancer were retrospectively evaluated. Among these patients, the mutation distributions of 1081 patients with metastatic lung adenocarcinoma were analyzed. A total of 150 patients with negative NGS panel or mutant KRAS followed up in our clinic were included. Clinical features, overall survival, first-line chemotherapy responses, and progression-free survival of NGS panel negative, KRAS(G12C), and KRAS(other) groups were compared. Results: In 1081 patients who underwent NGS from tumor tissue with the diagnosis of metastatic lung adenocarcinoma, 296 (27%) NGS panel negative and 276 (26%) KRAS mutant patients were detected. Among these patients, 150 patients whose data were available were 71 (47.3%) NGS panel negative, 54 (36%) KRAS(other), and 25 (16.7%) KRAS(G12C). Clinical features, brain metastasis, and first-line chemotherapy response were similar among groups. Bone metastases were detected more often in the NGS panel negative group (p = 0.03). The median follow-up was 8.4 months. Overall, 107 deaths had occurred at the time of analysis. There was no difference in overall survival (p = 0.56) or progression-free survival (p = 0.71) among NGS panel negative, KRAS(other), and KRAS(G12C) patients. Conclusion: There is no difference in overall survival, first-line chemotherapy response, or progression-free survival among patients with NGS panel negative, KRAS(G12C), or KRAS(other) metastatic lung adenocarcinoma. Bone metastases were observed more frequently in the NGS panel negative group.Öğe An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea(Tubitak Scientific & Technological Research Council Turkey, 2023) Cakcak, Ibrahim Ethem; Aytin, Yusuf Emre; Sayin, Sezin; Kucukarda, Ahmet; Gokyer, Ali; Gokmen, Ivo; Ozcan, ErkanBackground/aim: In our study, we aimed to investigate the protective effects of Saccharomyces boulardii on abemaciclib-induced diarrhea model, which is a commonly used drug in breast cancer. Materials and methods: Thirty rats were divided into 3 groups as control (Group 1), abemaciclib (Group 2), and abemaciclib + Saccharomyces boulardii (Group 3) groups. The clinical status, body weight, and defecation status were monitored daily. At the end of the 15-day experiment period, the rats were killed with high-dose anesthesia and the resected small intestine segments were evaluated histopathologically. Lesions were classified according to thickening of the villus, inflammation and edema of mucosa and intraepithelial leukocyte accumulation. Then, mean values of both crypt depths and villi thicknesses were calculated for each rat. Normal distribution assumption was controlled with the Shapiro-Wilk test. One-way analysis of variance for normally distributed variables in the comparisons of more than two independent groups and Kruskal-Wallis test for nonnormally distributed variables were used. The significance value was accepted as 0.05. Results: There was one death in Group 3, but none in the others. There were no findings of mucositis in Group I. There was mild diarrhea and weight loss in only one rat in Group 1. For the comparison of the severity of diarrhea (72.5%/39%) and weight loss (72.5%/45%), a decrease was found in Group 3 according to Group 2 (p < 0.01). Histopathological findings such as edema, inflammation, and intraepithelial leukocyte accumulation also showed a decrease in Group 3 compared to Group 2 (p < 0.01). Conclusion: Saccharomyces boulardii should be considered as a treatment option in abaemaciclib (chemotherapy)-induced diarrhea. Further comparative studies and in vivo human randomized controlled studies can be conducted in the future.Öğe Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review(Mosby-Elsevier, 2021) Gokyer, Ali; Sayin, Sezin; Kucukarda, Ahmet; Celik, Mehmet; Guldiken, Sibel; Cicin, IrfanSinonasal type hemangiopericytoma is a rare soft tissue tumor. Oncogenic osteomalacia (tumor-induced osteomalacia) is a rare syndrome that develops especially due to benign mesenchymal tumors. Nonspecific general bone pain and weakness delay the diagnosis and treatment of oncogenic osteomalacia, and it is difficult to determine the localization of the primary tumor causing oncogenic osteomalacia. A 43-year-old male patient with nasal hemangiopericytoma with symptoms of oncogenic osteomalacia is presented. The patient had musculoskeletal complaints at first and was diagnosed with lumbar disc herniation and surgery was performed. When his complaints recurred 1 year later, he was re-evaluated and diagnosed with hypophosphatemic osteomalacia. Despite the various treatments he received, his complaints did not decrease but increased, so a detailed examination was decided. When the positive PHEX mutation and very high fibroblast growth factor 23 level were detected, PET-CT imaging was performed with a pre diagnosis of possible oncogenic osteomalacia, but no finding was found. Then he was evaluated with Ga68 DOTATATE, and the soft tissue mass filling the right ethmoidal sinus was detected. Due to the relation of the mass with surrounding structures, it was considered unsuitable for total excision and incomplete surgical excision was performed. Pathologic evaluation revealed sinonasal type hemangiopericytoma (glomangiopericytoma). A significant remission in the patient's complaints was observed after the operation. Young patients with osteomalacia with unknown causes should be evaluated for malignancy, and screening and further examinations should be performed. (c) 2020 Elsevier Inc. All rights reserved.Öğe Prognostic Factors for Survival in Transverse Colon Cancers(Springer, 2022) Kucukarda, Ahmet; Gokyer, Ali; Sayin, Sezin; Gokmen, Ivo; Ozcan, Erkan; Kostek, Osman; Hacioglu, Muhammet BekirBackground Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure. Patients and Methods We evaluated local and locally advanced TCC patients between 2007 and 2020 years for demographics data, symptoms, treatment status, and histopathological and molecular features. Results Overall, 107 TCC patients were included in this study. According to the molecular data analysis of 44, 35, and 23 patients for MSI, RAS, and BRAF status, respectively, 7 (15.9%) were MSI-H, 13 (37.1%) were RAS mutant, and 11 (47.8%) had BRAF V600E mutation. The median follow-up time was 31.5 months. Median disease-free survival (DFS) was 5.19 months, and median OS was 88.3 months for the whole study population. The tumor stage was the most significant prognostic factor for DFS and OS. Although BRAF mutation was not a significant marker for DFS, it was an independent prognostic marker for OS (HR 3.90 95% CI 1.42-10.7). There were no statistically significant differences between proximal two-thirds and distal one-third tumor location. Conclusion TCC has molecular features and prognostic factors more likely RCC and no differences between proximal and distal sub-parts. BRAF V600E mutation status is an independent predictor of survival even in the early stages of TCC.Öğe Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma(Springer, 2022) Kucukarda, Ahmet; Erdogan, Bulent; Gokyer, Ali; Sayin, Sezin; Gokmen, Ivo; Ozcan, Erkan; Hacioglu, Muhammet BekirPurpose We aimed to identify the prognostic and predictive values of post-treatment prognostic nutritional index (PNI) and PNI dynamics in nasopharyngeal cancer patients (NPC) in this study. Methods One hundred seven non-metastatic NPC patients were included. PNI was calculated by using the following formula: [10 x serum albumin value (gr/dL)] + [0.005 x total lymphocyte count (per mm3)]. ROC analysis was used for determining prognostic PNI values and univariate and multivariate statistical analyses for prognostic characterization of PNI. Results The statistically significant cut-off values for pre- and post-treatment PNI were 50.65 and 44.75, respectively. Of the pre-treatment PNI analysis, PNI <= 50.65 group had shorter loco-regional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS). Furthermore, for post-treatment PNI analysis, PNI <= 44.75 group had shorter LRRFS and OS. In univariate analysis, only pre-treatment PNI was associated with LRRFS and DMFS, while pre- and post-treatment PNI were both associated with OS. In multivariate analysis, both PNI were independent prognostic markers for OS. In the combined analysis, pre- and post-treatment PNI, differences between the groups were statistically significant, and the PNI dynamics was an independent prognostic indicator for OS. Conclusion PNI is a useful, independent prognostic marker for non-metastatic NPC patients. It is used for either pre- or post-treatment patients. Furthermore, changes in pre-treatment PNI value after curative treatment is a significant indicator for OS.Öğe Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity(Future Medicine Ltd, 2021) Kucukarda, Ahmet; Sayin, Sezin; Gokyer, Ali; Aykan, Musa Baris; Karadurmus, Nuri; Cicin, IrfanLay abstract Immune checkpoint inhibitors are used with increasing frequency in cancer therapy. New side effects associated with these drugs have been identified. Air accumulation between the pleural membranes, which envelop the lungs and protect them in the ventilation function, without trauma may occur after using these drugs. We present here two cases that were treated with these drugs and developed this side effect. Patients with newly developed shortness of breath during this treatment should be careful about side effects such as this. Background: We present two cases of secondary pneumothorax after immunotherapy in two different clinics. Case summary: A 25-year old female patient with metastatic osteosarcoma, treated with atezolizumab. Grade 2 pneumonitis developed twice in the first year. Treatment was continued after recovery and areas of pneumonitis and pneumothorax were observed on computed tomography. No other reason could be found to cause pneumothorax. Pneumothorax resorbed spontaneously during follow-up. A 36-year old female patient treated with nivolumab for metastatic renal cell carcinoma (RCC), areas of pneumonitis and pneumothorax were only found as the cause of dyspnea. After treatment, remission was achieved on computed tomography findings. Pneumothorax was detected for the second time during continued therapy, and immunotherapy stopped permanently. Conclusion: These cases, indicate that immunotherapy can cause secondary immune-related pneumothorax based on immune pneumonitis.Öğe Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn's disease: A case report(Elsevier, 2020) Gokyer, Ali; Kucukarda, Ahmet; Sayin, Sezin; Keskin, Fatma Elif Usturali; Cicin, IrfanIntroduction: Colovesical fistulas are one of the most frequent complications in fistulizing Crohn's disease. Fistulizing Crohn's disease and tumor coexistence may lead to tumor spread through the fistula. Case report: In this study, a 62-year-old male patient with colon cancer spreading to bladder mucosa through the colovesical fistula due to Crohn's disease is presented. He was treated and followed up for Crohn's disease and in the routine follow-up colonoscopy, a mass was observed in sigmoid colon. Computed tomography demonstrated the mass as a local disease. The patient underwent both left hemicolectomy and due to intraoperative colovesical fistula, subsequently, fistulectomy. Pathologic evaluation revealed stage 1 adenocarcinoma of the colon. Transurethral resection was performed for postoperative evaluation and a mass was detected and resected in the bladder. Pathologic findings of resected specimens were consistent with metastasis of adenocarcinoma of the colon. The clinical features, diagnosis and treatment data were analyzed retrospectively and it was thought that the existing tumor spreads to the bladder through the colovesical fistula due to no invasion into the muscularis propria layer of the bladder. Management and outcome: Since muscle invasion was not detected in the bladder after TUR-T, cystectomy was not planned. 8 cycles of systemic adjuvant chemotherapy (Oxaliplatin and Capecitabine) were planned for 6 months. Gastroenterology consultation was requested for Crohn's disease treatment. It was recommended to discontinue azathioprine and continue with adalimumab therapy. Discussion: Colovesical fistula may develop in Crohn's disease that is not in remission and the fistulae can lead the metastasis of tumors.
